Cancer-Related Anorexia and Cachexia

Understanding and managing cancer anorexia-cachexia syndrome — the leading cause of weight loss, muscle wasting, and treatment intolerance in cancer patients

Key Points

• Cancer anorexia-cachexia syndrome (CACS) affects 50–80% of cancer patients and is directly responsible for 20–30% of all cancer-related deaths — it is not merely a side effect but a distinct life-threatening syndrome.
• Cachexia is defined as ≥5% unintentional weight loss in 6 months (or ≥2% with BMI <20), with ongoing muscle wasting driven by tumor-induced inflammation — it cannot be fully reversed by nutritional support alone.
• The cardinal inflammatory mediators are IL-6, TNF-α, IL-1, and proteolysis-inducing factor (PIF), which simultaneously suppress appetite centrally and accelerate skeletal muscle proteolysis.
• High-calorie oral nutritional supplements (ONS) improve quality of life and reduce weight loss but do not reverse established cachexia — they must be started early, before significant muscle mass is lost.
• Megestrol acetate and medroxyprogesterone improve appetite and weight in 30–40% of patients but the weight gained is predominantly fat, not lean muscle mass, and megestrol carries significant thromboembolic and adrenal suppression risks.
• Cachexia is staged (pre-cachexia → cachexia → refractory cachexia) — refractory cachexia in patients with a life expectancy under 3 months should shift the management focus from reversal to symptom management and comfort.

Definition, Staging, and Epidemiology

Cancer anorexia-cachexia syndrome (CACS) is a multifactorial metabolic syndrome characterized by ongoing skeletal muscle loss (with or without fat mass loss) that cannot be fully reversed by conventional nutritional support, and that leads to progressive functional impairment. It is distinct from starvation (where fat is preferentially lost and muscle is partially spared) and from simple malnutrition (which can be corrected by feeding). **International Consensus Definition (Fearon K, et al., Lancet Oncol 2011):** Cachexia is defined by at least one of: - Weight loss >5% over the past 6…

Pathophysiology — Why Cachexia Cannot Be Fed Away

The fundamental insight is that cancer cachexia is driven by systemic inflammation and tumor-host metabolic reprogramming — not merely by reduced caloric intake. This is why simply feeding more calories cannot reverse it. **1. Pro-inflammatory cytokine-mediated anorexia:** Tumors and the immune response to tumors produce IL-6, TNF-α, IL-1β, interferon-gamma, and leukemia inhibitory factor (LIF). These cytokines act on the hypothalamus to suppress appetite through multiple mechanisms: - Stimulate hypothalamic melanocortin signaling (MC4R activation → anorexia) - Reduce hypothalamic…

Assessment and Screening

Early detection of pre-cachexia and cachexia is critical — intervention is most effective before significant muscle mass is lost. **Recommended screening at every oncology visit:** - **Weight**: trend over 1–6 months; >5% unintentional weight loss triggers formal assessment - **Appetite assessment**: use validated tools such as the Anorexia/Cachexia Subscale of the FAACT (Functional Assessment of Anorexia/Cachexia Treatment), the ESPEN NRS-2002, or simply ask: "How is your appetite? Have you noticed eating less than usual?" - **Diet history**: estimated caloric intake vs. estimated needs…

Nutritional Management

Nutritional intervention is the foundation of CACS management. The goals are to maximize nutrient intake within the constraints of the disease, slow weight and muscle loss, and maintain quality of life — not to achieve weight gain at all costs. **Caloric and protein targets:** - Energy: 25–30 kcal/kg/day for most cancer patients; 30–35 kcal/kg/day for patients with active cancer and hypermetabolism - Protein: 1.2–2.0 g/kg/day (higher end for patients with active muscle wasting and those in active treatment) - Prioritize protein over total calories — adequate protein intake preserves lean…

Pharmacologic Management of Anorexia and Cachexia

Pharmacologic treatment targets appetite stimulation, anti-inflammation, anabolism, and metabolic normalization. **1. Megestrol acetate (Megace) and medroxyprogesterone:** Progestational agents — the most widely used pharmacologic appetite stimulants in cancer cachexia. - **Megestrol acetate**: 400–800 mg/day oral suspension; improves appetite in 30–40% of patients; increases body weight — but the weight gained is predominantly fat and water, NOT lean muscle mass - **Evidence**: multiple RCTs demonstrate improved appetite and sense of well-being; no proven survival benefit - **Major risks**:…